From: Effects of Tocilizumab in COVID-19 patients: a cohort study
 | All (N = 60) | Died (n = 9) |
---|---|---|
Age, median (range), years | 54 (26–87) | 58 (33–84) |
Male, n (%) | 40 (66.7) | 8 (88.9) |
Ethnicity | ||
 Hispanic | 38 (63.3) | 6 (66.7) |
 Black | 14 (23.3) | 2 (22.2) |
 White | 7 (11.7) | 1 (11.1) |
 Asian | 1 (1.7) | 0 (0.0) |
Comorbidities | ||
 Obese (BMI > 30) | 35 (58.3) | 6 (66.7) |
 Hypertension | 32 (53.3) | 8 (88.9) |
 Diabetes | 15 (25.0) | 3 (33.3) |
 Congestive heart failure | 4 (6.7) | 1 (11.1) |
 Coronary artery disease | 1 (1.7) | 0 (0.0) |
 Asthma | 4 (6.7) | 0 (0.0) |
 COPD | 1 (1.7) | 1 (11.1) |
 Obstructive sleep apnea | 2 (3.3) | 0 (0.0) |
 HIV | 1 (1.7) | 0 (0.0) |
 Transplant | 1 (1.7) | 0 (0.0) |
Concomitant therapies | ||
 Hydroxychloroquine | 52 (86.7) | 8 (88.9) |
 Corticosteroids | 32 (53.3) | 5 (55.6) |
 Inhaled nitric oxide | 5 (8.3) | 1 (11.1) |
 Intravenous immunoglobulin (IVIG) | 4 (6.6) | 0 (0.0) |
 Tacrolimus | 2 (3.3) | 1 (11.1) |
 Convalescent plasma | 2 (3.3) | 0 (0.0) |
 Plasmapheresis | 1 (1.7) | 0 (0.0) |
Time from symptom onset to hospital admission, median (range), days | 6 (1–14) | 7 (1–14) |
Time from hospital admission to receiving tocilizumab, median (range), days | 2 (0–12) | 1 (0–4) |
Time from symptom onset to receiving tocilizumab, median (range), days | 8 (1–21) | 8 (1–15) |